Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > When do we hit 0.1, 0.2, 1$?

<< Previous

Bullboard Posts

Next >>

Post by 011Pekingon Mar 04, 2021 12:16pm

139 Views

Post# 32715661

When do we hit 0.1, 0.2, 1$?

I'd love to hear your opinion.

I've been reading so much bullshit, some say well be at this 0.05 level until 2022... but why shouldn't we go higher until then? I think we'll see 0.5 at least this summer 1-3 months mby?

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables